

of CT and RT improved survival in pts with PCNHL. Despite whole brain RT, patients with CR recurred within the brain, outside the primary site. As combined MTX and RT had adverse effects on cognitive functions, whole brain RT is questionable in pts with PCNHL.

1351

POSTER

### Primary breast lymphoma

J. Cotrina, C. Carracedo, J. Abugattas, J. Arias Stella, L. Leon, C. Vigil, R. Velarde, L. Casanova, M. Zaharia, C. Vallejos. *Instituto de Enfermedades Neoplásicas, MEDICINE, Av. Angamos Este 2520, 34 Lima, Peru*

**Background:** Primary breast lymphoma is a rare disease, represents 0.1% of breast malignancies and 2.2% of all extranodal non Hodgkin's lymphomas. The literature has reported about 300 cases. We reviewed the experience of the Instituto de Enfermedades Neoplásicas (Lima-Peru) from 1952 to 1997.

**Methods:** We found 17 patients with primary breast lymphoma. Twelve received treatment in our institution, and 11 of this had complete treatment. The follow-up was from 12 to 120 months. The chemotherapy and radiation therapy were the elective treatment. Some patients were subject to surgery.

**Results:** All the patients were females. The mean age was 45.4 years (15–69 years). The mean period of disease was 3.9 months. The symptom was breast mass in 11 patients and 1 had skin erythema. The histologic were: WF:G, 5 (41.7%); WF:A, 2 (16.7%); WF:H, 2 (16.7%); WF:B, 1 (8.3%); WF:I, 1 (8.3%); and WF:F, 1 (8.3%). 4 stage IE, 4 stage IIE, and 4 stage IVE. Of 11 patients who received complete treatment, Five patients were treated with CHOP and COPP. (3 patients with cytologic diagnostic of carcinoma, receiving chemotherapy after surgery) Six patients received Chemo and radiation therapy; One patient died three years after received treatment for other cause, and 7 are alive at present time, all without disease evidence. Three patient after two years developed recurrence with subtype diffuse, large cell WF:G lymphoma. Of all patients who are alive or died without disease evidence, 2 were stage IE 3 stage IIE; and 3 were stage IVE with follow-up of 3 to 9 years. Of the 9 patients with 3 or more years of follow-up, 6 (66.7%) are free disease, and the 8 patients who are alive and coming to control, 5 (62.5%) are free disease at 5 or more years.

**Conclusions:** The diffuse, large cell WF:G lymphoma was the predominant histologic subtype. The chemotherapy and radiation therapy are the treatment of choice with a 62.5% of survival at 5 years for any stage.

1352

POSTER

### Bendamustine in the therapy of lowgrade malignant lymphomas

J. Preiss, H.K. Heck, P. Schmidt. *Department of Hematology and Medical oncology, Caritasclinic St. Theresia, Saarbruecken, Germany*

**Purpose:** Palliative treatment of advanced low/intermediate grade lymphomas is characterized by high remission rates, short remission duration and necessity of subsequent therapies. Lacking curability, quality of life is a major issue. A therapeutic option is the alkylating agent bendamustine (be); is associated with little toxicity and good tolerability, even in older patients. We present the data of a retrospective analysis of 34 patients, treated with be single agent or combination therapy with mitoxantrone (mitx).

**Methods:** 34 patients (age 48–82, mean 63) were treated with be (21) or be/mitx(13). Disease entities: follicle center (fc) 13, lymphoplasmocytic (lp) 9, lymphocytic (lc) 9, mantle cell (mc) lymphomas 2, plasmacytomas (pl) 3. Treatment: be 100 mg/m<sup>2</sup>, d 1–3, with or without mitx 6 mg/m<sup>2</sup>, d 1–2. Mean number of cycles was 3.8.

**Results:** Overall remission rate was 61% (29% CR, 32% PR); NC 24%, PD 15%. Results, discriminated by histologic subtype: CR: fc 6, lp 3, lc 1; PR: fc 3, lp 2, lc 4, mc 2; NC: fc 2, lp 4, lc 1, pl 1; PD: fc 2, lc 1, pl 2. Remission duration was 8–11 months for patients with CR, PR and NC. be single agent therapy resulted in 48% CR/PR, the combination regimen in 69% CR/PR.

**Toxicity:** Hematologic: 8 cases of grade 3/4 leukopenia/thrombocytopenia. Nausea/emesis grade 2 was observed in 11 patients, grade 3 in 3 patients. Alopecia (g 3) was only seen in patient.

**Conclusion:** Be and mitx are effective drugs in the palliative treatment of low/intermediate grade malignant lymphomas. Single agent and combination treatment are well tolerated; dose limiting is hematotoxicity. To further define the role of bendamustine-based therapy, randomized studies, comparing it with actual standard treatment are necessary.

1353

POSTER

### HCV and non-Hodgkin lymphomas: A retrospective study

A. Abbadessa, V. Belsito Petrizzi, L. Liguori, O. Villani, S. Iaccarino, C. De Luca, G. Abbadessa, P. Ferravante, G. De Simone, M. De Rienzo. *Dip. Intern. Clin. Sper. "F. Magrassi", II Università Napoli, Italy*

**Purpose:** As reported by several studies, the prevalence of HCV-infection in B-cell lymphoproliferative disorders (19%) appears to be significantly higher than in other hematological malignancies as in the general population (2.3%); the correlation emerges also from recent virological and histopathological data. In a retrospective study based on a series of 91 patients affected by B-cell non-Hodgkin lymphoma (NHL) or other lymphoproliferative disorders diagnosed in our Institution, the prevalence of HCV infection was evaluated.

**Methods:** HCV serological markers were investigated at diagnosis in 43 women and 48 men affected by B-cell lymphoma, except when a diagnosis of chronic HCV-related hepatitis was documented.

**Results:** 11 cases of a series of 91 consecutive patients resulted positive for serological markers of HCV-infection (12.1%). Among these 4 were low grade, 3 high grade, and 2 intermediate grade lymphomas second W.F.; the other cases included an angiotropic large cell lymphoma and an unclassified B-cell lymphoproliferative disorder.

**Conclusion:** These data are consistent with an association between HCV-infection and B-cell lymphoproliferative disorders. However the relevant diffusion of HCV-infection in South Italy (1–5%) and the small size of the study require further analysis to indicate a possible role of HCV in the lymphomagenesis.

1354

POSTER

### Can we include apoptotic index in prognostic scores in patients with myelodysplastic syndrome

A.D. Bogdanović<sup>1</sup>, D.P. Trpinac<sup>2</sup>, G.M. Janković<sup>1</sup>, V. Čemerikić<sup>1</sup>, V. Bumbaširević<sup>2</sup>, M.D. Čolović<sup>1</sup>. <sup>1</sup>*Inst of Hematology, University Clinical Center;* <sup>2</sup>*Inst. of Histology, School of Medicine, Beograd, Yugoslavia*

**Objective and Methods:** To evaluate the prognostic significance of apoptotic index (AI) and to compare AI with other prognostic scores, Bornemouthe (BS) and Spanish score (SS) in 30 patients MDS. The bone marrow samples of 30 pts. with MDS were embedded for semithin morphological analysis (Leukemia 1997) and number of cells in apoptosis were counted and expressed as percentage (AI). According to FAB there were RA and RARS (8 + 3 pts), RAEB + RAEB-t (14 + 2) and 3 pts with CMML. Analysis have been calculated on 50% survival basis (SRV<sub>50%</sub>).

**Results:** According to FAB, pts with low risk (RA + RARS) have significant better survival than RAEB/t (OS<sub>5y</sub> 80% vs SRV<sub>50%</sub> 20 m., log rank p < 0.01). We have introduced apoptotic prognostic score APS (low AI < 2.5, intermediate AI 2.5–3.99 and high AI > 4). In analysis of APS that patients with low APS survive better than others (>68 m) while pts with intermediate and high APS have worse survival (24 and 17 m). The survival according to APS was similar to survival according to BS and SS. We also found that pts. with low and high APS have significantly different BS (t test p < 0.05) but not SS.

**Conclusion:** Our analysis is influenced by the small number of analyzed patients but we think that apoptotic prognostic score with cutoff of at least of 3% of apoptotic cells (AI) can be used as a simple and reliable prognostic factor in patients with myelodysplastic syndrome and can be included in future prognostic score system.

1355

PUBLICATION

### Antileukemic activity and induction of apoptosis by gemcitabine

M. Georgieva<sup>1</sup>, S.M. Konstantinov<sup>2</sup>, M.R. Berger<sup>2</sup>. <sup>1</sup>*Dept. of Carcinogenesis, National Oncological Center, Sofia, Bulgaria;* <sup>2</sup>*Unit of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany*

Gemcitabine (Gem) is a new deoxycytidine analog which inhibits cellular DNA synthesis by masked chain termination. We studied the cytotoxic efficacy of Gem by MTT-assay in human myeloid HL-60 and K-562 leukemic cells and by investigating DNA fragmentation. BCR-ABL positive K-562 cells were less sensitive to Gem than AML derived HL-60 cells. Gel electrophoresis of DNA isolated from Gem treated HL-60 and SKW-3 showed oligo-nucleosomal fragmentation typical for programmed cell death (5 µM for 20 h). Under the conditions of a cell-free system consisting of cytosolic

fraction from treated and nuclei from untreated cells we demonstrated that K-562 nuclei underwent apoptotic DNA fragmentation when incubated with cytosolic extract from Gem treated SKW-3 cells. The resistance of K-562 cells can be explained by the expression of BCR-ABL which prevents the apoptotic cell death. Cytosine arabinoside (Ara C) and Gem showed similar cytotoxic profiles on K-562 cells after 48 h incubation (IC50 > 100  $\mu$ M for Ara C and IC50 > 40  $\mu$ M for Gem). The simultaneous exposure (72 h) of K-562 to Gem and hexadecylphosphocholine (HPC) caused synergistic cytotoxicity. 24 h incubation of K-562 cells with 50  $\mu$ M Gem followed by 50  $\mu$ M HPC for 24 h caused optimal growth inhibition. Gem was found to be effective against freshly isolated blasts from a patient with relapsed AML as measured by the MTT-assay. Taken together our data indicate that Gem can be of benefit for patients with leukemias not responding to standard protocols.

1356

PUBLICATION

### Cyclophosphamide, vincristine, epirubicin and prednisolone (ceop-100) in aggressive Non Hodgkin's lymphoma (ANHL)

S.E. Bavbek<sup>1</sup>, M. Basaran<sup>1</sup>, K. Uygun<sup>1</sup>, S. Alici<sup>1</sup>, E. Darendeliler<sup>1</sup>, H. Onat<sup>1</sup>. <sup>1</sup>Oncology Institute, University of Istanbul Istanbul, Turkey

Combination chemotherapy (CT) with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) remains the standard treatment for aNHL. We replaced adriamycin with the less cardiotoxic anthracycline, epirubicin, in a phase II trial. Between 1993–1998, 89 patients (pts) with intermediate/high grade NHL were accrued into the trial. CEOP-100 consisted of cyclophosphamide 750 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup>, vincristine 1.4 mg/m<sup>2</sup> on day 1, and prednisolone 100 mg days 1–5 every 21 days. Growth factors were used for secondary prophylaxis of neutropenic fever. The treatment plan included 4 cycles of CT followed by involved-field radiotherapy in stage I–IIA disease; advanced disease received 6 cycles of CT and radiotherapy to bulky nodes. WHO criteria for toxicity was used. Pts who did not achieve complete response (CR) after the first 3 cycles were given salvage CT and taken off the study. The median age was 45 (range: 15–76), the male/female ratio 58/31. There were 19 pts with stage I, 34 with stage II, 25 with stage III and 11 with stage IV disease; 32 pts (36%) had B symptoms. Histology (Working Formulation) was intermediate grade in 79 and high grade in 10 pts. 449 cycles of CT were evaluable for toxicity; 81% of the pts completed the treatment. Delay > 1 week occurred in 16% of the pts; 10% needed dose modification. Toxicity (grade III–IV) was recorded as follows: neutropenia 10%, anemia 8%, thrombocytopenia 3%, mucositis 5% of the cycles. Five episodes of neutropenic fever developed. One patient died with acute heart failure. Of the 85 pts with measurable disease, 76% achieved CR, 18% had partial response (PR); one patient progressed during CT. Fourteen pts (22%) with initial CR relapsed; 12 relapsed during the first year and died after being refractory to salvage CT. One of the 2 pts who relapsed after one year responded to salvage CT and is still in second remission. Median follow-up is 34 months; median disease-free survival is 15.5 and median overall survival is 19 months. The cumulative 3-year and 5-year survival is 49% (95% CI: 43–55) and 44% (95% CI: 37–51) respectively. The CEOP-100 regimen is an active and tolerable outpatient regimen applicable in aNHL. Ongoing trials of regimens with better CR rates will hopefully result in better survival.

1357

PUBLICATION

### Prognostic factors in primary gastric non Hodgkin's lymphoma

M. Basaran<sup>1</sup>, S.E. Bavbek<sup>1</sup>, S. Alici<sup>1</sup>, K. Uygun<sup>1</sup>, O. Dogan<sup>2</sup>, M. Agan<sup>2</sup>, E. Darendeliler<sup>1</sup>, H. Onat<sup>1</sup>. <sup>1</sup>Oncology Institute, University of Istanbul, Istanbul; <sup>2</sup>Istanbul Medical Faculty, Pathology Department, Istanbul, Turkey

Fifty-two patients (pts) with primary gastric nonHodgkin's lymphoma (PGNHL) treated and followed between 1991–1998 were retrospectively analysed for presentation characteristics and prognostic factors. Histology (Working Formulation), performance status (PS-WHO), stage (Ann Arbor), bulky disease (>6 cm.), beta-2-microglobulin (B2MG), lactic dehydrogenase (LDH), surgery, and response to chemotherapy (CT) were included in the prognostic analysis. Median age was 60 (range: 23–75); male/female ratio was 1:1. Twenty-one pts had a distinguishable MALT (mucosa-associated lymphoid tissue) based lymphoma; 8 had low grade and 13 had high grade MALT histology. The other 31 pts did not have MALT association; 2 had follicular mixed, 16 had diffuse large cell, 9 had diffuse mixed cell and 4 had diffuse immunoblastic histology. The stomach was diffusely involved in 81% of the pts. Seventeen pts had stage I, 15 had II, 14 had III and 6 had IV disease; 42% had B symptoms. Thirty-seven pts applied after surgery;

14 had subtotal and 23 had total gastrectomy. CT was given to 34 (92%) of the pts after surgery; a total of 49 pts received CT and 98% of the CT given was anthracycline-based. Pts with stage I disease and high grade histology received adjuvant CT after surgery. Response was evaluated in 35 pts who had measurable disease after surgery of unresectable gastric lymphoma; complete response (CR) was achieved in 74%. With combined of surgery and CT, the CR rate was 79%. PS > 2, stage IV disease, and lack of CR to CT were the adverse prognostic factors for survival. Surgery, LDH and B2MG levels did not affect survival. Of all pts who underwent surgery, only two pts did not receive CT, one of them is alive without disease. The 5-year overall survival was 65%; the 5-year survival was 69% in pts with unresected advanced stage disease, 73% in pts with subtotal gastrectomy and 60% in pts with total gastrectomy. There was no significant difference in survival between pts with or without surgery, although pts without surgery had advanced, unresectable disease. We conclude that the role of surgery in primary gastric lymphoma is still unclear. It is evident that only a fraction of pts can be cured by surgery alone, and the role of surgery in addition to CT remains to be determined in randomized studies.

1358

PUBLICATION

### Aberrant immunoglobulin (Ig) heavy chain glycosilation in igg multiple myeloma (MM)

I. Aurer<sup>1</sup>, G. Lauc<sup>2</sup>, D. Rendic<sup>2</sup>, B. Labar<sup>1</sup>. <sup>1</sup>University Hospital Center Rebrow, Division of Hematology, Zagreb; <sup>2</sup>Faculty of Pharmacy and Biochemistry, Department of Biochemistry and Molecular Biology, Croatia, Croatia

Glycosilation is the most important posttranslational modification of proteins in eukaryotic cells. While cells spend a large amount of energy on this process its importance in normal physiology and disease is largely unclear. Ig heavy chains are glycosilated mainly on the Fc portion and this is thought to be important in receptor binding and possibly control of clonal expansion. In MM tumor cells produce large amounts of a single Ig molecule. We compared glycosilation patterns in 18 IgG MMs and 19 matched controls by measuring levels of galactose and sialic acid moieties attached to heavy chains. IgG was purified using ammonium-sulfate precipitation and anion exchange chromatography, separated by denaturing electrophoresis and transferred onto PVDF membrane. Galactose and sialic acid moieties attached to heavy chains were detected using biotin-labeled RCA I and lectin, respectively. Galactosilation of MM chains was significantly less than that of normal controls (mean 283 relative units (RU), std. deviation 80 RU, vs. mean 352 RU, std. dev. 4 RU, p = 0.002). Sialylation was not different (mean 193 RU, std. dev. 83 RU, vs. mean 183 RU, std. dev. 30 RU), however some cases of MM had very low or very high sialylation. Neither galactosilation, nor sialylation correlated with clinical and biochemical parameters: sex, age, light chain type, disease status, disease duration, type of treatment, IgG or  $\beta$ 2-microglobulin concentration. In MM the production of monoclonal immunoglobulin is accompanied by reduced galactosilation and in some cases aberrant sialylation. The clinical significance of these findings is presently unclear.

1359

PUBLICATION

### Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma

H. Szelenyi, J. Siehl, H.D. Menssen, E. Thiel, U. Keilholz. <sup>1</sup>Freie Universität Berlin, Universitätsklinikum Benjamin Franklin, Berlin, Germany

Previously we showed that the combination of Cyclophosphamid, bolus Adriamycin (doxorubicin) and Dexamethasone (CAD) is an efficacious therapy with a 75% objective response rate in patients with multiple myeloma. Data in the literature suggest that prolonged infusion of doxorubicin is even more efficacious. Liposomal encapsulation of doxorubicin (Caelyx<sup>®</sup>) shows a half time of 39 hours. Furthermore, studies show that Caelyx is less cardiotoxic as the free drug which is important for patients with multiple myeloma with a mean age in the 6th live decade. Therefore we initiated a phase I/II, dose escalating trial in patients with multiple myeloma with a CAD regimen in which doxorubicin is substituted by Caelyx (CLAD).

Treatment regimen was: Cyclophosphamid 200 mg/m<sup>2</sup> day 1–4, Liposomal Doxorubicin (Caelyx) in two dose levels day 1 and Dexamethasone 40 mg day 1–4. Dose levels of calyx are 10 mg/m<sup>2</sup> and 20 mg/m<sup>2</sup>. Treatment was repeated every three weeks.

So far, 6 patients (3 women, 3 men) were included in our study on dose level 1. Median age was 68 years (range 61–83). IgA- myeloma was seen in 1 patient, IgG in 14 patients and light chain disease in 1 patient. All patients